Cardio3 BioSciences announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy European Phase III trial for C3BS-CQR-1 in Belgium.
http://www.science20.com/news_articles/phase_iii_clinical_trial_regenerative_medicine_heart_failure-96950
http://www.science20.com/news_articles/phase_iii_clinical_trial_regenerative_medicine_heart_failure-96950
No comments:
Post a Comment